| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:MANBA_KDR |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: MANBA_KDR | KinaseFusionDB ID: KFG3276 | FusionGDB2.0 ID: KFG3276 | Hgene | Tgene | Gene symbol | MANBA | KDR | Gene ID | 4126 | 3791 | |
| Gene name | mannosidase beta | kinase insert domain receptor | ||||||||||
| Synonyms | MANB1 | CD309|FLK1|VEGFR|VEGFR2 | ||||||||||
| Cytomap | 4q24 | 4q12 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | beta-mannosidasebeta-mannosidase Alysosomal beta A mannosidasemannanasemannasemannosidase, beta A, lysosomal | vascular endothelial growth factor receptor 2fetal liver kinase-1kinase insert domain receptor (a type III receptor tyrosine kinase)protein-tyrosine kinase receptor Flk-1soluble VEGFR2tyrosine kinase growth factor receptor | ||||||||||
| Modification date | 20240403 | 20240411 | ||||||||||
| UniProtAcc | Q9NQG1 | P35968 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000226578, ENST00000505239, | ENST00000263923, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: MANBA [Title/Abstract] AND KDR [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ||||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | KDR | GO:0001934 | positive regulation of protein phosphorylation | 19033661 |
| Tgene | KDR | GO:0008284 | positive regulation of cell population proliferation | 7929439 |
| Tgene | KDR | GO:0008360 | regulation of cell shape | 7929439 |
| Tgene | KDR | GO:0010629 | negative regulation of gene expression | 26879375 |
| Tgene | KDR | GO:0018108 | peptidyl-tyrosine phosphorylation | 10037737|10102632 |
| Tgene | KDR | GO:0030335 | positive regulation of cell migration | 7929439 |
| Tgene | KDR | GO:0035924 | cellular response to vascular endothelial growth factor stimulus | 10102632|11387210|19033661|21885851|23529610 |
| Tgene | KDR | GO:0038084 | vascular endothelial growth factor signaling pathway | 21885851 |
| Tgene | KDR | GO:0043410 | positive regulation of MAPK cascade | 11387210 |
| Tgene | KDR | GO:0046777 | protein autophosphorylation | 10037737|10102632|19033661 |
| Tgene | KDR | GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 10102632|11387210|15215251|21885851 |
| Tgene | KDR | GO:0050927 | positive regulation of positive chemotaxis | 7929439 |
| Tgene | KDR | GO:0051770 | positive regulation of nitric-oxide synthase biosynthetic process | 10600473 |
| Tgene | KDR | GO:0051894 | positive regulation of focal adhesion assembly | 12820653 |
| Tgene | KDR | GO:0051897 | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | 9804796 |
| Tgene | KDR | GO:1904881 | cellular response to hydrogen sulfide | 26879375 |
| Tgene | KDR | GO:2000352 | negative regulation of endothelial cell apoptotic process | 9804796 |
| Tgene | KDR | GO:2001028 | positive regulation of endothelial cell chemotaxis | 21885851 |
| Kinase Fusion gene breakpoints across MANBA (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across KDR (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| CCLE | GAMG | MANBA | chr4 | 103635595 | KDR | chr4 | 55948802 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:/:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MANBA | KDR |
| FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC. {ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:10368301, ECO:0000269|PubMed:10600473, ECO:0000269|PubMed:11387210, ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:1417831, ECO:0000269|PubMed:15026417, ECO:0000269|PubMed:15215251, ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:16966330, ECO:0000269|PubMed:17303569, ECO:0000269|PubMed:18529047, ECO:0000269|PubMed:19668192, ECO:0000269|PubMed:19834490, ECO:0000269|PubMed:20080685, ECO:0000269|PubMed:20224550, ECO:0000269|PubMed:20705758, ECO:0000269|PubMed:21893193, ECO:0000269|PubMed:25825981, ECO:0000269|PubMed:7929439, ECO:0000269|PubMed:9160888, ECO:0000269|PubMed:9804796, ECO:0000269|PubMed:9837777}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of MANBA_KDR |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| KDR | P35968 | human | PFN1 | P07737 | Y129 | GLINkkCyEMAsHLR | Profilin |
| KDR | P35968 | human | KDR | P35968 | Y1054 | FGLARDIykDPDyVR | PK_Tyr_Ser-Thr |
| KDR | P35968 | human | KDR | P35968 | Y1175 | AQQDGKDyIVLPISE | |
| KDR | P35968 | human | KDR | P35968 | Y1214 | VCDPKFHyDNtAGIS | |
| KDR | P35968 | human | KDR | P35968 | Y951 | RFRQGKDyVGAIPVD | PK_Tyr_Ser-Thr |
| KDR | P35968 | human | KDR | P35968 | Y996 | EEAPEDLyKDFLTLE | PK_Tyr_Ser-Thr |
| KDR | P35968 | human | KDR | P35968 | Y1059 | DIykDPDyVRKGDAR | PK_Tyr_Ser-Thr |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| KDR | ID | Description | 0.00e+00 |
| KDR | GO:0010634 | positive regulation of epithelial cell migration | 1.40e-02 |
| KDR | GO:0010632 | regulation of epithelial cell migration | 1.40e-02 |
| KDR | GO:0021700 | developmental maturation | 1.40e-02 |
| KDR | GO:0060562 | epithelial tube morphogenesis | 1.40e-02 |
| KDR | GO:0010631 | epithelial cell migration | 1.40e-02 |
| KDR | GO:0090132 | epithelium migration | 1.40e-02 |
| KDR | GO:0090130 | tissue migration | 1.40e-02 |
| KDR | GO:0001667 | ameboidal-type cell migration | 1.75e-02 |
| KDR | GO:1903010 | regulation of bone development | 1.75e-02 |
| KDR | GO:0048563 | post-embryonic animal organ morphogenesis | 1.75e-02 |
| KDR | GO:0098885 | modification of postsynaptic actin cytoskeleton | 1.75e-02 |
| KDR | GO:1904181 | positive regulation of membrane depolarization | 1.75e-02 |
| KDR | GO:0003157 | endocardium development | 1.75e-02 |
| KDR | GO:2001214 | positive regulation of vasculogenesis | 1.75e-02 |
| KDR | GO:0060837 | blood vessel endothelial cell differentiation | 1.75e-02 |
| KDR | GO:1900029 | positive regulation of ruffle assembly | 1.75e-02 |
| KDR | GO:2001028 | positive regulation of endothelial cell chemotaxis | 1.75e-02 |
| KDR | GO:0051770 | positive regulation of nitric-oxide synthase biosynthetic process | 1.75e-02 |
| KDR | GO:2001212 | regulation of vasculogenesis | 1.75e-02 |
| KDR | GO:0009886 | post-embryonic animal morphogenesis | 1.75e-02 |
| KDR | GO:0043129 | surfactant homeostasis | 1.75e-02 |
| KDR | GO:0038083 | peptidyl-tyrosine autophosphorylation | 1.75e-02 |
| KDR | GO:0048569 | post-embryonic animal organ development | 1.75e-02 |
| KDR | GO:0051767 | nitric-oxide synthase biosynthetic process | 1.75e-02 |
| KDR | GO:0051769 | regulation of nitric-oxide synthase biosynthetic process | 1.75e-02 |
| KDR | GO:0051900 | regulation of mitochondrial depolarization | 1.75e-02 |
| KDR | GO:0090141 | positive regulation of mitochondrial fission | 1.75e-02 |
| KDR | GO:0099010 | modification of postsynaptic structure | 1.75e-02 |
| KDR | GO:0035584 | calcium-mediated signaling using intracellular calcium source | 1.75e-02 |
| KDR | GO:0051882 | mitochondrial depolarization | 1.75e-02 |
| KDR | GO:0061042 | vascular wound healing | 1.75e-02 |
| KDR | GO:0002070 | epithelial cell maturation | 1.75e-02 |
| KDR | GO:0035162 | embryonic hemopoiesis | 1.75e-02 |
| KDR | GO:2001026 | regulation of endothelial cell chemotaxis | 1.75e-02 |
| KDR | GO:0002053 | positive regulation of mesenchymal cell proliferation | 1.75e-02 |
| KDR | GO:0050927 | positive regulation of positive chemotaxis | 1.75e-02 |
| KDR | GO:0050926 | regulation of positive chemotaxis | 1.75e-02 |
| KDR | GO:0051894 | positive regulation of focal adhesion assembly | 1.75e-02 |
| KDR | GO:0099563 | modification of synaptic structure | 1.77e-02 |
| KDR | GO:0090140 | regulation of mitochondrial fission | 1.77e-02 |
| KDR | GO:0001945 | lymph vessel development | 1.77e-02 |
| KDR | GO:0035767 | endothelial cell chemotaxis | 1.77e-02 |
| KDR | GO:0150117 | positive regulation of cell-substrate junction organization | 1.77e-02 |
| KDR | GO:1900027 | regulation of ruffle assembly | 1.77e-02 |
| KDR | GO:0010464 | regulation of mesenchymal cell proliferation | 1.77e-02 |
| KDR | GO:0060055 | angiogenesis involved in wound healing | 1.77e-02 |
| KDR | GO:0051497 | negative regulation of stress fiber assembly | 1.77e-02 |
| KDR | GO:0060074 | synapse maturation | 1.77e-02 |
| KDR | GO:0090050 | positive regulation of cell migration involved in sprouting angiogenesis | 1.77e-02 |
Top |
Related Drugs to MANBA_KDR |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning MANBA-KDR and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to MANBA_KDR |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |